A detailed history of Royal Bank Of Canada transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4,692 shares of ELYM stock, worth $19,284. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,692
Previous 3,468 35.29%
Holding current value
$19,284
Previous $17,000 11.76%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$4.11 - $5.42 $5,030 - $6,634
1,224 Added 35.29%
4,692 $19,000
Q3 2024

Nov 14, 2024

BUY
$4.98 - $8.93 $13,854 - $24,843
2,782 Added 405.54%
3,468 $17,000
Q2 2024

Aug 14, 2024

BUY
$2.6 - $10.2 $1,619 - $6,354
623 Added 988.89%
686 $4,000
Q1 2024

Nov 05, 2024

SELL
$2.54 - $2.98 $1,582 - $1,856
-623 Reduced 90.82%
63 $0
Q1 2024

May 15, 2024

BUY
$2.54 - $2.98 $68 - $80
27 Added 75.0%
63 $0
Q4 2023

Feb 14, 2024

SELL
$2.45 - $2.85 $49 - $57
-20 Reduced 35.71%
36 $0
Q3 2023

Nov 14, 2023

SELL
$2.48 - $3.15 $171 - $217
-69 Reduced 55.2%
56 $0
Q2 2023

Aug 14, 2023

BUY
$2.34 - $3.72 $292 - $465
125 New
125 $0
Q3 2022

Nov 14, 2022

BUY
$2.72 - $3.97 $225 - $329
83 Added 296.43%
111 $0
Q2 2022

Aug 15, 2022

SELL
$2.77 - $8.4 $947 - $2,872
-342 Reduced 92.43%
28 $0
Q1 2022

May 16, 2022

SELL
$8.01 - $13.15 $9,876 - $16,213
-1,233 Reduced 76.92%
370 $3,000
Q4 2021

Feb 14, 2022

BUY
$8.61 - $20.47 $7,086 - $16,846
823 Added 105.51%
1,603 $17,000
Q3 2021

Nov 15, 2021

BUY
$14.45 - $28.61 $11,271 - $22,315
780 New
780 $14,000

Others Institutions Holding ELYM

About Eliem Therapeutics, Inc.


  • Ticker ELYM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,567,700
  • Market Cap $109M
  • Description
  • Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...
More about ELYM
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.